<DOC>
	<DOCNO>NCT00602225</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . Colony stimulate factor , G-CSF , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . PURPOSE : This phase I trial study side effect best dose clofarabine see well work give together cytarabine G-CSF treating patient relapse refractory acute myeloid leukemia</brief_summary>
	<brief_title>Clofarabine , Cytarabine , G-CSF Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose clofarabine , dose-limiting toxicity combination clofarabine cytarabine G-CSF priming , treatment patient relapse refractory AML . SECONDARY OBJECTIVES : I . To determine hematological non-hematological side effect profile combination clofarabine , cytarabine , G-CSF . II . To determine efficacy clofarabine combination cytarabine G-CSF priming treatment patient relapse refractory AML . III . To determine disease-free overall survival therapy clofarabine , cytarabine , G-CSF relapse refractory AML . OUTLINE : This dose escalation study clofarabine . PART I : INDUCTION THERAPY : Patients receive clofarabine IV 1 hour cytarabine IV 2 hour day 1-5 , filgrastim ( G-CSF ) subcutaneously daily begin 24 hour prior chemotherapy continue blood count recover . Patients residual leukemia ( &gt; = 5 % blast morphology ) day 14 blast remain &gt; 5 % day 21 receive second course induction therapy . CONSOLIDATION THERAPY : Patients receive clofarabine , cytarabine , G-CSF induction therapy . Patients may receive second course consolidation therapy depend response whether additional therapy ( e.g. , stem cell transplant donor lymphocyte infusion ) plan . PARTS II III : Patients receive induction therapy consolidation therapy part 1 . After completion study treatment , patient follow every 3 month 2 year annually 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>ECOG performance status 02 Capable understanding investigational nature , potential risk benefit study , able provide valid inform consent Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment Male female patient must willing use effective contraceptive method study minimum 6 month study treatment Serum Total Direct bilirubin = &lt; 1.5 time upper limit normal ( ULN ) Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) = &lt; 2.5 time ULN Diagnosis acute myeloid leukemia WHO criteria , either relapsed refractory ; acute promyelocytic leukemia [ acute promyelocytic leukemia ( 15 ; 17 ) ( q22 ; q12 ) variant ] would eligible failure regimen contain arsenic trioxide Serum creatinine = &lt; 1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dl , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m^2 Alkaline phosphatase = &lt; 2.5 time ULN Use investigational agent within 30 day initiation anticancer therapy within 2 week study entry exception hydroxyurea , intrathecal therapy leukemic meningitis Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) Pregnant lactate patient Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result Have severe concurrent disease , history serious organ dysfunction , disease involve heart , kidney , liver ( include symptomatic hepatitis , venoocclusive disease , hepatic graftversushost disease [ acute &gt; = grade 2 ] ) , organ system dysfunction No concomitant cytotoxic therapy investigational therapy allow study exception intrathecal therapy leukemic meningitis ; intrathecal therapy must give within 24 hour 5 day Clofarabine/Cytarabine treatment period To extent possible , use nephrotoxic ( e.g. , vancomycin , amphotericin B , etc ) hepatotoxic ( e.g. , voriconazole , cyclosporine , etc ) agent avoided clofarabine ; use alternative medication ( e.g. , herbal botanical anticancer purpose ) permit entire study period Current concomitant chemotherapy , radiation therapy , immunotherapy specify protocol More two fail induction attempt initial diagnosis current relapse ; patient enrol part III protocol , patient must first salvage relapse le one year complete remission , salvage initial induction chemotherapy Allogeneic transplant recipient immunosuppression treatment GVHD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>